Skip to content

Psychopharmacology

ISSN 1432-2072, 0033-3158

637 papers in the library · 20,322 citations · publishing 1971-2026

Papers

Sort Most recent Most cited

MDMA self-administration fails to alter the behavioral response to 5-HT(1A) and 5-HT(1B) agonists.

Psychopharmacology April 2016 Dane Aronsen, Susan Schenk

Regular use of the street drug, ecstasy, produces a number of cognitive and behavioral deficits. One possible mechanism for these deficits is functional changes in serotonin (5-HT) receptors as a consequence of prolonged 3,4 methylenedioxymethamphetamine (MDMA)-produced 5-HT release. Of particular interest are the 5-HT(1A) and 5-HT(1B) receptor subtypes since they have been implicated in...

Repeated administration of the 5-HT₁B/₁A agonist, RU 24969, facilitates the acquisition of MDMA self-administration: role of 5-HT₁A and 5-HT₁B receptor mechanisms.

Psychopharmacology April 2016 Dane Aronsen, Natasha Bukholt, Susan Schenk

3,4 Methylenedioxymethamphetamine (MDMA) preferentially stimulates the release of serotonin (5-HT) that subsequently produces behavioral responses by activation of post-synaptic receptor mechanisms. The 5-HT1A and 5-HT1B receptors are both well localized to regulate dopamine (DA) release, and have been implicated in modulating the reinforcing effects of many drugs of abuse, but a role in...

The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents.

Psychopharmacology April 1, 2016 Adam L. Halberstadt, Natalia Slepak, James Hyun et al.

Methoxetamine (MXE) is a ketamine analog sold online that has been subject to widespread abuse for its dissociative and hallucinogenic effects. Previous studies have shown that MXE has high affinity for the phencyclidine (PCP) binding site located within the channel pore of the NMDA receptor (NMDAR), but little is known about its behavioral effects. Dissociative anesthetics such as ketamine and...

DOI: 10.1007/s00213-016-4203-3 (opens in new tab) Full text (opens in new tab) Behavioral pattern monitor Ketamine isomers Locomotor activity Methoxetamine +3

Abnormal medial prefrontal cortex activity in heavy cannabis users during conscious emotional evaluation.

Psychopharmacology March 1, 2016 Michael J Wesley, Joshua A Lile, Colleen Hanlon et al.

Long-term heavy cannabis users (cannabis users) who are not acutely intoxicated have diminished subconscious neural responsiveness to affective stimuli. This study sought to determine if abnormal processing extends to the conscious evaluation of emotional stimuli. Functional magnetic resonance imaging (fMRI) was used to examine brain activity as cannabis users (N = 16) and non-cannabis-using...

Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: a single-dose study

Psychopharmacology March 1, 2016 HeeSeung Lee, Grace Y. Wang, Louise E. Curley et al.

Rationale Piperazine-based designer drugs such as benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been marketed and sold as legal alternatives to dexamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) until 2008 in New Zealand. When administered in combination, BZP + TFMPP have been reported to produce drug-drug synergism in rodents by stimulating the release of...

Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities

Psychopharmacology November 27, 2015 Joaquim Soler, Matilde Elices, Alba Franquesa et al. 212 citations

BackgroundAyahuasca is a psychotropic plant tea used for ritual purposes by the indigenous populations of the Amazon. In the last two decades, its use has expanded worldwide. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine-oxidase-inhibiting properties. Acute administration induces an introspective dream-like...

The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Psychopharmacology November 2015 Sanna K Janhunen, Heta Svärd, John Talpos et al.

Current treatments for schizophrenia have modest, if any, efficacy on cognitive dysfunction, creating a need for novel therapies. Their development requires predictive animal models. The N-methyl-D-aspartate (NMDA) hypothesis of schizophrenia indicates the use of NMDA antagonists, like subchronic phencyclidine (scPCP) to model cognitive dysfunction in adult animals. The objective of this study...

DOI: 10.1007/s00213-015-3954-6 (opens in new tab) Full text (opens in new tab) Adult rat Cognition Schizophrenia Subchronic phencyclidine +3

Comparing the effects of subchronic phencyclidine and medial prefrontal cortex dysfunction on cognitive tests relevant to schizophrenia.

Psychopharmacology November 1, 2015 K A L McAllister, A C Mar, D E Theobald et al.

It is becoming increasingly clear that the development of treatments for cognitive symptoms of schizophrenia requires urgent attention, and that valid animal models of relevant impairments are required. With subchronic psychotomimetic agent phencyclidine (scPCP), a putative model of such impairment, the extent to which changes following scPCP do or do not resemble those following dysfunction of...

DOI: 10.1007/s00213-015-4018-7 (opens in new tab) Full text (opens in new tab) Animal model Associative learning Discrimination Glutamate +6

Opposing effects of glutamatergic and GABAergic pharmacological manipulations on a visual perception task with relevance to schizophrenia.

Psychopharmacology November 2015 John Talpos, John Riordan, Joseph Olley et al.

Numerous psychiatric disorders and neurodegenerative diseases have been associated with differences in visual perception, and it has been proposed that the treatment of these differences may represent a novel means to treat disorders like schizophrenia. Unfortunately, few methods exist to study visual perception in pre-clinical species. The purpose of the present study was to adapt a task of...

DOI: 10.1007/s00213-015-3964-4 (opens in new tab) Full text (opens in new tab) Autism Nmda receptor Schizophrenia Touchscreen +2

LSD enhances the emotional response to music.

Psychopharmacology October 2015 Mendel Kaelen, Frederick S. Barrett, Leor Roseman et al.

There is renewed interest in the therapeutic potential of psychedelic drugs such as lysergic acid diethylamide (LSD). LSD was used extensively in the 1950s and 1960s as an adjunct in psychotherapy, reportedly enhancing emotionality. Music is an effective tool to evoke and study emotion and is considered an important element in psychedelic-assisted psychotherapy; however, the hypothesis that...

Effect of norbinaltorphimine on ∆⁹-tetrahydrocannabinol (THC)-induced taste avoidance in adolescent and adult Sprague-Dawley rats.

Psychopharmacology September 2015 Shaun M Flax, Alison Wakeford, Kejun Cheng et al.

The aversive effects of ∆(9)-tetrahydrocannabinol (THC) are mediated by activity at the kappa opioid receptor (KOR) as assessed in adult animals; however, no studies have assessed KOR involvement in the aversive effects of THC in adolescents. Given that adolescents have been reported to be insensitive to the aversive effects induced by KOR agonists, a different mechanism might mediate the...

Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations

Psychopharmacology July 31, 2015 Michael Kometer, Thomas Pokorny, Erich Seifritz et al. 165 citations

RationaleDuring the last years, considerable progress has been made toward understanding the neuronal basis of consciousness by using sophisticated behavioral tasks, brain-imaging techniques, and various psychoactive drugs. Nevertheless, the neuronal mechanisms underlying some of the most intriguing states of consciousness, including spiritual experiences, remain unknown.ObjectivesTo elucidate...

Oxytocin and MDMA ('Ecstasy') enhance social reward in rats.

Psychopharmacology July 2015 Linnet Ramos, Callum Hicks, Alex Caminer et al.

Oxytocin (OT), vasopressin (AVP) and 3,4 methylenedioxymethamphetamine (MDMA, 'Ecstasy') all increase social interaction in rats, perhaps by enhancing the rewarding value of social encounters. Here, we used the conditioned place preference (CPP) paradigm to assess the intrinsic rewarding effects of OT, AVP and MDMA, and whether these effects are enhanced by the presence of a conspecific, or a...

Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway

Psychopharmacology May 20, 2015 J. Jett, Angela M. Boley, M. Girotti et al.

Acute low-dose administration of the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, produces rapid and sustained antidepressant-like effects in humans and rodents. Recently, we found that the long-lasting effect of ketamine on the forced swim test requires ventral hippocampal (vHipp) activity at the time of drug administration. The medial prefrontal cortex (mPFC), a target of the...

Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile

Psychopharmacology May 19, 2015 R. Joules, O. Doyle, A. J. Schwarz et al. 77 citations

Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has been studied in relation to the glutamate hypothesis of schizophrenia and increases dissociation, positive and negative symptom ratings. Ketamine effects brain function through changes in brain activity; these activity patterns can be modulated by pre-treatment of compounds known to attenuate the effects of ketamine on glutamate...

fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Psychopharmacology May 2015 C A Roberts, C Montgomery

Ecstasy use is associated with cognitive impairment, believed to result from damage to 5-HT axons. Neuroimaging techniques to investigate executive dysfunction in ecstasy users provide a more sensitive measure of cognitive impairment than behavioural indicators. The present study assessed executive access to semantic memory in ecstasy polydrug users and non-users. Twenty ecstasy polydrug users...

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia

Psychopharmacology March 11, 2015 Amir I. A. Ahmed, G. A. H. van den Elsen, A. Colbers et al.

Data on safety, pharmacodynamics, and pharmacokinetics of tetrahydrocannabinol (THC) are lacking in dementia patients. In this randomized, double-blind, placebo-controlled, crossover trial, we evaluated the safety, pharmacodynamics, and pharmacokinetics of THC in ten patients with dementia (mean age 77.3 ± 5.6). For 12 weeks, participants randomly received oral THC (weeks 1–6, 0.75 mg; weeks...

LSD enhances suggestibility in healthy volunteers.

Psychopharmacology February 2015 R L Carhart-Harris, Mendel Kaelen, M G Whalley et al.

Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control. The present study sought to test the effect of LSD on suggestibility in a modern research study. Ten healthy volunteers were administered with intravenous (i.v.) LSD (40-80 μg) in a within-subject...

Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.

Psychopharmacology 2015 Veronica Serra, Liana Fattore, Maria Scherma et al. 26 citations

Salvinorin A is a recreational drug derived from Salvia divinorum, a sage species long used as an entheogen. While salvinorin A has potent hallucinogenic properties, its abuse potential has not been assessed consistently in controlled behavioural and neurochemical studies in rodents. This study aimed to assess salvinorin A abuse potential by measuring its capacity to establish and maintain...

DOI: 10.1007/s00213-014-3641-z (opens in new tab) Full text (opens in new tab) The drug Addiction addictive properties Compulsive self-administration Drug-seeking behavior +3

Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.

Psychopharmacology December 2014 Claudine C Hunault, Koen B E Böcker, R K Stellato et al.

An increase in the potency of the cannabis cigarettes has been observed over the past three decades. In this study, we aimed to establish the impact of Δ9-tetrahydrocannabinol (THC) on the rating of subjective effects (intensity and duration of the effects), up to 23 % THC potency (69 mg THC) among recreational users. Recreational users (N = 24) smoked cannabis cigarettes with four doses of THC...

MDMA: a social drug in a social context.

Psychopharmacology October 5, 2014 Matthew G. Kirkpatrick, Harriet de Wit 43 citations

RationaleThe drug ±3,4-methylenedioxymethamphetamine (MDMA, "ecstasy," "molly") is thought to produce prosocial effects and enhance social interaction. However, in most laboratory studies to date, the participants have been tested under nonsocial conditions, which may not simulate the effects the drug produces in more naturalistic social settings.MethodsHealthy experienced MDMA users...

Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.

Psychopharmacology October 1, 2014 Bruce E. Blough, Antonio Landavazo, Ann M Decker et al. 99 citations

Synthetic hallucinogenic tryptamines, especially those originally described by Alexander Shulgin, continue to be abused in the USA. The range of subjective experiences produced by different tryptamines suggests that multiple neurochemical mechanisms are involved in their actions, in addition to the established role of agonist activity at serotonin 2A (5-HT₂A) receptors. This study evaluated the...

DOI: 10.1007/s00213-014-3557-7 (opens in new tab) Full text (opens in new tab) Hallucinogens Psychedelics Psychoactive substances Hallucinogenic compounds +12

D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression

Psychopharmacology July 24, 2014 Ruin Moaddel, D. Luckenbaugh, Ying Xie et al.

(R,S)-ketamine is a rapid and effective antidepressant drug that produces a response in two thirds of patients with treatment-resistant depression (TRD). The underlying biochemical differences between a (R,S)-ketamine responder (KET-R) and non-responder (KET-NR) have not been definitively identified but may involve serine metabolism. The aim of the study was to examine the relationship between...

Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis

Psychopharmacology July 19, 2014 Judith Nottage, James Stone, Robin Murray et al. 34 citations

RATIONALE: An acute challenge with delta-9-tetrahydrocannabinol (THC) can induce psychotic symptoms including delusions. High electroencephalography (EEG) frequencies, above 20 Hz, have previously been implicated in psychosis and schizophrenia. OBJECTIVES: The objective of this study is to determine the effect of intravenous THC compared to placebo on high-frequency EEG. METHODS: A double-blind...

The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice

Psychopharmacology July 2, 2014 Theresa M. Carbonaro, Amy J. Eshleman, Michael J. Forster et al. 67 citations

RationaleSerotonin 5-HT2A and 5-HT2C receptors are thought to be the primary pharmacological mechanisms for serotonin-mediated hallucinogenic drugs, but recently there has been interest in metabotropic glutamate (mGluR2) receptors as contributors to the mechanism of hallucinogens.ObjectiveThe present study assesses the role of these 5-HT and glutamate receptors as molecular targets for two...